Literature DB >> 9928373

Helicobacter pylori infection and the pathogenesis of duodenal ulceration.

M M Walker1, J E Crabtree.   

Abstract

Helicobacter pylori is a gram-negative spiral bacterium confined to the habitat of gastric-type epithelium. H. pylori causes duodenal ulceration by a cumulative effect of antral predominant gastritis with increased acid secretion, consequent gastric metaplasia in the duodenum (a site of further colonization by H. pylori), duodenitis, reduced duodenal bicarbonate secretion, and mucosal damage. Bacterial factors influence outcome. Major determinants are the production of a vacuolating toxin and the presence of CagA, an immunodominant product of a nonconserved gene cagA, a marker for the cag pathogenicity island that encodes virulence genes involved in induction of epithelial chemokine responses. In ulcer patients the mucosal immune response is polarized to a T-helper-1 (Th1) cell-mediated response, which may contribute to mucosal damage. Eradication of H. pylori restores acid output to normal. Loss of both acid and bacteria halts gastroduodenitis and allows ulcer healing. Gastric metaplasia does not regress in the short term.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9928373     DOI: 10.1111/j.1749-6632.1998.tb11114.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  18 in total

1.  Modulation of Helicobacter pylori induced interleukin-8 synthesis in gastric epithelial cells mediated by cag PAI encoded VirD4 homologue.

Authors:  J E Crabtree; D Kersulyte; S D Li; I J Lindley; D E Berg
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori.

Authors:  Dirk Bumann; Sevil Aksu; Meike Wendland; Katharina Janek; Uschi Zimny-Arndt; Nicolas Sabarth; Thomas F Meyer; Peter R Jungblut
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

3.  cDNA array analysis of cag pathogenicity island-associated Helicobacter pylori epithelial cell response genes.

Authors:  J M Cox; C L Clayton; T Tomita; D M Wallace; P A Robinson; J E Crabtree
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Celecoxib inhibits Helicobacter pylori colonization-related factors.

Authors:  Jing Wang; Wei-Hong Wang; Jiang Li; Fang-Xun Liu
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

Review 5.  Laboratory tests for the evaluation of Helicobacter pylori infections.

Authors:  R M Nakamura
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

6.  Gastric helicobacter infection induces a Th2 phenotype but does not elevate serum cholesterol in mice lacking inducible nitric oxide synthase.

Authors:  Melanie Ihrig; Mark T Whary; Charles A Dangler; James G Fox
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

7.  Anti-CagA immunoglobulin G responses correlate with interleukin-8 induction in human gastric mucosal biopsy culture.

Authors:  T Ando; G I Perez-Perez; K Kusugami; M Ohsuga; K C Bloch; M J Blaser
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

8.  Lack of stage-specific proteins in coccoid Helicobacter pylori cells.

Authors:  Dirk Bumann; Hajar Habibi; Biao Kan; Monika Schmid; Christian Goosmann; Volker Brinkmann; Thomas F Meyer; Peter R Jungblut
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

9.  Multiple genes in the left half of the cag pathogenicity island of Helicobacter pylori are required for tyrosine kinase-dependent transcription of interleukin-8 in gastric epithelial cells.

Authors:  S D Li; D Kersulyte; I J Lindley; B Neelam; D E Berg; J E Crabtree
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

10.  IgG subclass response to Helicobacter pylori and CagA antigens in children.

Authors:  K Dzierzanowska-Fangrat; M Raeiszadeh; D Dzierzanowska; M Gladkowska-Dura; D Celinska-Cedro; J E Crabtree
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.